the role of lenvatinib in nsclc treatment
Published 7 years ago • 120 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
0:57
dr. taylor discusses the toxicities and impact of lenvatinib in the select trial
-
2:56
dr. finn on role of lenvatinib in hcc treatment paradigm
-
1:59
effect of age and lenvatinib treatment on os for patients with thyroid cancer
-
6:27
nccn guidelines for first-line treatment of rr-dtc
-
7:03
lenvatinib breakthrough designation, new drug applications for nsclc and sts, and more
-
1:22
discussing the phase ii study of lenvatinib/pembrolizumab in metastatic ccrcc
-
4:55
treatment approach to metastatic hepatocellular carcinoma
-
1:24
phase iii findings for lenvatinib in hcc
-
5:04
reviewing lenvatinib data for treatment in mhcc
-
1:33
adverse events inform treatment decisions in hcc for frontline lenvatinib versus sorafenib
-
4:16
frontline therapy for hcc: optimizing treatment selection
-
1:17
expectations for the treatment landscape of differentiated thyroid cancers in the future
-
2:52
effect of age and lenvatinib on os in thyroid cancer
-
0:58
the significance of the resorce trial in hcc
-
1:07
recent advancements for the treatment of liver cancer
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
6:42
the role of lenvatinib in advanced rcc
-
3:45
how goals help to determine frontline treatment in hcc